Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Outset Medical

Thumbnail
January 18, 2021

Astounding success greets newly public device makers

2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.

Thumbnail
January 14, 2021

Medtechs rake in the venture cash

In terms of private investments, 2020 was the year of the liquid biopsy.

Article image
Vantage logo
July 14, 2020

Medtech venture investors live up to their name

Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.

Article image
Vantage logo
January 10, 2019

Fewer than 200 medtech VC rounds closed in 2018

Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.

Article image
Vantage logo
January 16, 2018

Medtech funding ventures into the unknown

In a truly extraordinary year, the top 10 venture rounds made up more than half of the total invested.

Article image
Vantage logo
July 12, 2017

Medtech venture funding total hits all-time high

So far, 2017 has been a record-breaker in a number of ways – and none of them bode well for start-ups.

Vantage logo
May 05, 2017

Snippet roundup: Novartis's allogeneic CAR-T drive and Astra's IL-4 interest

Vantage logo
January 19, 2016

Huge medtech venture rounds mean start-ups starve

Vantage logo
July 15, 2015

Medtech venture financing crisis worsens

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
January 18, 2021

Aducanumab tops 2021’s biggest potential launches

Vantage logo
January 19, 2021

The pandemic releases its grip on clinical trials

Vantage logo
January 21, 2021

2020 drug approvals rise despite Covid-19

Vantage logo
January 20, 2021

Glaxo joins the Covid-19 delay queue

Vantage logo
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.